- Home
- ESBA vs GLPG Comparison
ESBA vs GLPG Comparison
Compare ESBA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESBA
- GLPG
- Stock Information
- Founded
- ESBA N/A
- GLPG 1999
- Country
- ESBA United States
- GLPG Belgium
- Employees
- ESBA N/A
- GLPG N/A
- Industry
- ESBA
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ESBA
- GLPG Health Care
- Exchange
- ESBA NYSE
- GLPG Nasdaq
- Market Cap
- ESBA 2.0B
- GLPG 2.0B
- IPO Year
- ESBA 2013
- GLPG 2005
- Fundamental
- Price
- ESBA $7.50
- GLPG $31.73
- Analyst Decision
- ESBA
- GLPG Sell
- Analyst Count
- ESBA 0
- GLPG 4
- Target Price
- ESBA N/A
- GLPG $25.33
- AVG Volume (30 Days)
- ESBA 3.7K
- GLPG 284.6K
- Earning Date
- ESBA 01-01-0001
- GLPG 07-23-2025
- Dividend Yield
- ESBA 1.81%
- GLPG N/A
- EPS Growth
- ESBA 3.47
- GLPG N/A
- EPS
- ESBA 0.30
- GLPG N/A
- Revenue
- ESBA $762,039,000.00
- GLPG $311,493,731.00
- Revenue This Year
- ESBA N/A
- GLPG $0.78
- Revenue Next Year
- ESBA N/A
- GLPG N/A
- P/E Ratio
- ESBA $25.86
- GLPG N/A
- Revenue Growth
- ESBA 0.78
- GLPG 18.32
- 52 Week Low
- ESBA $6.39
- GLPG $22.36
- 52 Week High
- ESBA $11.50
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- ESBA 40.70
- GLPG 58.96
- Support Level
- ESBA $7.49
- GLPG $28.78
- Resistance Level
- ESBA $8.19
- GLPG $33.86
- Average True Range (ATR)
- ESBA 0.17
- GLPG 0.75
- MACD
- ESBA -0.05
- GLPG 0.12
- Stochastic Oscillator
- ESBA 17.86
- GLPG 55.84
About ESBA EMPIRE STATE REALTY OP LIM PARTNER
Empire State Realty OP LP is an NYC-focused real estate investment trust (REIT) that owns and operates a portfolio of well-leased, top-of-tier, modernized, amenitized, and well-located office, retail, and multifamily assets, conducts all of its business and owns substantially all of its assets. The firm operates in two segments, Real Estate and Observatory. Through the Real Estate segment, it offers services related to the ownership, management, operation, acquisition, repositioning and disposition of its real estate assets. Under the Observatory segment, it operates the two observatories of the Empire State Building. The company generates maximum revenue from the Real Estate segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.